Canadian application, no grantCanada
Combination of a gaba-a alpha 5 inverse agonist and a nicotinic agonist
CA 2324237 A1 · Owner: Merck Sharp & Dohme Limited · Inventors: Dawson, Gerard Raphael
Overview
Drawings and full text
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to a combination of a nicotinic agonist and an inverse agonist of the GABAA .alpha.5 receptor subtype and the use of the , combination in treating neurodegenerative conditions such as Alzheimer's Disease.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 16, 1999. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended March 16, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 16, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
FiledMarch 16, 1999
GrantedNo grant recorded
Term endedMarch 16, 2019
Patent numberCA 2324237 A1
Classification (IPC)A61K31/50 +2 more
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.